ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 2151

Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 2144

JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 2015

JAK Selectivity Did Not Affect to the Incidence of Malignancies in the Real-World Setting: Data from a Multicenter Observational Study in Japan

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 2153

Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 1781

Knee Pain Is Highly Associated with Ankle/Foot Pain, Arch Height, and Arch Flexibility: The Johnston County Osteoarthritis Project

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 2027

Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1862

Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial

Muscle Biology, Myositis and Myopathies Poster II

1:00PM-3:00PM: Abstract Number: 1860

Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis

Muscle Biology, Myositis and Myopathies Poster II

1:00PM-3:00PM: Abstract Number: 1698

LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 2163

Lipid Profile in Scleroderma Patients and the Associations of Its Changes with Disease-specific Features

Systemic Sclerosis and Related Disorders – Clinical Poster III

1:00PM-3:00PM: Abstract Number: 1963

Lipid Screening and Statin Use in Rheumatoid Arthritis Patients in an Underserved Population

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 2056

Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 2111

Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 2009

Long-term Outcome of a Treat-to-target Strategy in Elderly-onset Rheumatoid Arthritis with Chronic Lung Diseases

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 2121

Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database

Spondyloarthritis Including PsA – Treatment Poster III: PsA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].